Parasitological, pathological and functional studies on the effects of IFN α 2B in murine hepatic schistosomiasis

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 31, Issue 1 SUPPL., 2000, Pages 1-7

  Eissa, Maha M ^a   Baddour, Nahed M ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTHELMINTIC AGENT; CYCLINE; PRAZIQUANTEL;

ANIMAL; ARTICLE; DRUG COMBINATION; LIVER FUNCTION TEST; METABOLISM; MOUSE; PARASITE IDENTIFICATION; PARASITIC LIVER DISEASE; PATHOLOGY; SCHISTOSOMIASIS;

ANIMALS; ANTHELMINTICS; DRUG THERAPY, COMBINATION; INTERFERON ALFA-2B; LIVER DISEASES, PARASITIC; LIVER FUNCTION TESTS; MICE; PARASITE EGG COUNT; PRAZIQUANTEL; PROLIFERATING CELL NUCLEAR ANTIGEN; SCHISTOSOMIASIS;

EID: 0042689610     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Al Nakib B, Alnakib W, Bayoumi A, Al Liddawi H, Bashir AA. Hepatitis B virus (HBV) markers among patients with chronic liver disease in Kuwait. Trans R Soc Trop Med Hyg 1982;76:348-50.
2. Baddour NM, van Thiel DH, Mourshidi S. Behavior of fibroblasts in culture in fibrotic liver. Alexandria: Faculty of Medicine, University of Alexandria 1993. MD Thesis.
3. Baddour NM, Younis L. Causal relationship between hepatic inflammation and hepatocyte regeneration in chronic hepatitis. N Egypt J Hepatol Gastrenterol Infect Dis 1996;4:27-35.
4. Billau A, De Somer P, Edy VG, De Clerco E, Hermans H. Human fibroblast interferon for clinical trials: Pharmacokinetics and tolerability in experimental animals and humans. Antimicrob Agents Chemother 1979;16:53-63.
5. Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
6. Brinckerhoff CE, Guyre PM. Increased proliferation of human synovial fibroblasts treated with recombinant immune interferon. J Immunol 1985;134:3142-6.
7. Cheever AW. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull WHO 1968;399:328-31.
8. Cheever AW, Macedonia JG, Subrato D, Cheever EA, Mosimann JE. Persistence of eggs and hepatic fibrosis following treatment of Schistosoma mansoni-infected mice. Aw J Trop Med Hyg 1992;46:752-8.
9. Chin T, Winterowd GE, Krzesicki RF, Sanders ME. Role of cytokines in inflammatory synovitis. Arthr Rheum 1990;33:1776-86.
10. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-5.
11. De Maeyer E. Immunomodulation by interferon. An appraisal. Ann Inst Pasteur/Immunol 1985;136:67-91.
12. El-Temsahi MM. Master degree in parasitology. Faculty of Medicine, University of Alexandria, 1984. (Thesis)
13. Friedman SL. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-34.
14. Giboda M, Smith JM, Prichard RK. Reduction in tissue egg load and maintenance of resistance to challenge in mice infected with Schistosoma mansoni, following combined treatment with praziquantel and an antifibrotic agent. Ann Trop Med Parasitol 1944;88:385-95.
15. Giboda M, Jacobs P, Smith JM, Miller SC. Immune response of mice infected with Schistosoma mansoni is modulated by anti fibrotic treatment. Ann Trop Med Parasitol 1995;899:415-24.
16. Goldberg B, Green H. Relation between collagen synthesis and collagen proline hydroxylase activity in mammalian cells. Nature 1969;221:267-9.
17. Gresser I. Biologic effects of interferon. J Invest Dermatol 1990;95:66-71.
18. Gresser AM. Perisinusoidal lipocytes and fibrogenesis. Gut 1994;35:1331-3.
19. Hunninghake GW, Hemken C, Brady M, Monik M. Immune interferon is a growth factor for human lung fibroblasts. Am Rev Resp Dis 1986;134:1025-9.
20. Knop J. Immunologic effects of interferon. J Invest Dermatol 1990;95:725-42.
21. Lyra LG, Reboucas G, Andrade ZA. Hepatitis B surface antigen carrier state in hepatosplenic schistosomiasis. Gastroenterol 1976;71:641-5.
22. Matsumoto K, Nakamura T. Hepatocyte growth factor: molecular structure and implications for a role in liver regeneration. J Gastroenterol 1991;6:509-19.
23. Michaolopoulus GK. Liver regeneration: molecular mechanisms of growth control. FASEB J 1990;4:176-87.
24. Moore S, Stein HW. Chromatography of amino acids on sulfonated polystyrene resins. Anal Chem 1958;30:1185-9.
25. Paul RG, Roodman ST, Cambell CR, Bodicke CJ, Perillo RP. HLA class I antigen expression as a measure of response to antiviral therapy of chronic hepatitis B. Hepatology 1991;13:820-5.
26. Peters M. Mechanism of action of IFN. Semin Liv Dis 1989;9:235-9.
27. Ramadori G, Neubauer K, Odenthal M, et al. The gene of hepatocyte growth factor is expressed in fat-storing cells of rat liver and is down regulated during cell growth and by transforming growth factor beta. Biochem Biophys Res Comm 1992;183:739-42.
28. th ed. WB Saunders 1991:803.
29. Van Thiel DH, Gavaler JS, Baddour N, Friedlander L, Wright HI. Treatment of putative non-A, non-C hepatitis with alpha interfelon: a preliminary trial. J Oklahoma State Med Assoc 1994;87:364-8.
30. Watson JM, Abd el Azim M. Comparative efficiency of various methods of infecting mice with Bilharzia mansoni. Ann Trop Med Parasitol 1949;43:41.
31. Wu CH, Giambrone MA, Howard DJ, Rojkind M, Wu GY. The nature of collagen in hepatic fibrosis in advanced murine schistosomiasis. Hepatology 1982;2:366-72.
32. Yoshioka K, Higashi Y, Yameda M, et al. Predictive factors in the response to IFN therapy in chronic hepatitis C. Liver 1995;15:57-62.